Rare case of hemorrhagic brain metastasis from hepatoblastoma

Yadav, Saroj S; Lawande, Malini; Patkar, Deepak; Pungavkar, S

doi:10.4103/1817-1745.97634

Cited by 5 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lung is the most common metastatic organ of hepatoblastoma. In addition to lung, brain and bone metastases have also been reported [12,47]. At the first diagnosis of hepatoblastoma, 17% of patients had pulmonary metastases [48].…”

Section: Treatment After Metastasismentioning

confidence: 99%

Diagnosis and Treatment of Hepatoblastoma: An Update

Zhu¹,

Dong²,

Chen³

et al. 2021

Liver Pathology

View full text Add to dashboard Cite

Hepatoblastoma is a rare but the most common solid tumor in children. The incidence is gradually increasing. The international collaboration among four centers in the world has greatly improved the prognosis of hepatoblastoma. They formed the Children's Hepatic Tumor International Collaboration (CHIC) to standardize the staging system (2017 PRETEXT system) and the risk factors for tumor stratification. Multimodal therapy has become the standard for the management of hepatoblastoma, including surgical resection, liver transplantation, chemotherapy, and so on. Surgery is the primary treatment of early stage hepatoblastoma. Threedimensional reconstruction is helpful for preoperative evaluation of large tumors, assisting extended hepatectomy for patients in PRETEXT III or IV. Neoadjuvant therapy is useful for reducing the tumor volume and increasing the resectability. Primary liver transplantation is recommended for advanced hepatoblastoma. The lungs are the most common metastatic organ, the treatment of which is critical for the patient's long-term survival. We reviewed the recent progress in the diagnosis and treatment of hepatoblastoma.

show abstract

Section: Treatment After Metastasismentioning

confidence: 99%

Diagnosis and Treatment of Hepatoblastoma: An Update

Zhu¹,

Dong²,

Chen³

et al. 2021

Liver Pathology

View full text Add to dashboard Cite

show abstract

2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)

et al. 2018

View full text Add to dashboard Cite

Imaging is crucial in the assessment of children with a primary hepatic malignancy. Since its inception in 1992, the PRETEXT (PRE-Treatment EXTent of tumor) system has become the primary method of risk stratification for hepatoblastoma and pediatric hepatocellular carcinoma in numerous cooperative group trials across the world. The PRETEXT system is made of two components: the PRETEXT group and the annotation factors. The PRETEXT group describes the extent of tumor within the liver while the annotation factors help to describe associated features such as vascular involvement (either portal vein or hepatic vein/inferior vena cava), extrahepatic disease, multifocality, tumor rupture and metastatic disease (to both the lungs and lymph nodes). This manuscript is written by members of the Children's Oncology Group (COG) in North America, the International Childhood Liver Tumors Strategy Group (SIOPEL) in Europe, and the Japanese Study Group for Pediatric Liver Tumor (JPLT; now part of the Japan Children's Cancer Group) and represents an international consensus update to the 2005 PRETEXT definitions. These definitions will be used in the forthcoming Trial to Pediatric Hepatic International Tumor Trial (PHITT).

show abstract

Analysis of risk factors for angiolymphatic invasion and establishment of a predictive nomogram for hepatoblastomas

Zhou

Yang

et al. 2022

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Rare case of hemorrhagic brain metastasis from hepatoblastoma

Cited by 5 publications

References 5 publications

Diagnosis and Treatment of Hepatoblastoma: An Update

Diagnosis and Treatment of Hepatoblastoma: An Update

2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)

Analysis of risk factors for angiolymphatic invasion and establishment of a predictive nomogram for hepatoblastomas

Contact Info

Product

Resources

About